Letter to the Editor Regarding: A Comprehensive Review on Copemyl                         ®

Giancarlo Comi; Ferdinando Nicoletti; Pier Luigi Canonico; Diego Centonze

doi:10.1007/s40120-018-0115-y

Letter to the Editor Regarding: A Comprehensive Review on Copemyl ^®

Giancarlo Comi, Ferdinando Nicoletti, Pier Luigi Canonico, Diego Centonze

Dipartimento di Scienze del Farmaco

Risultato della ricerca: Contributo su rivista › Lettera › peer review

Lingua originale	Inglese
pagine (da-a)	385-390
Numero di pagine	6
Rivista	Neurology and Therapy
Volume	7
Numero di pubblicazione	2
DOI	https://doi.org/10.1007/s40120-018-0115-y
Stato di pubblicazione	Pubblicato - 1 dic 2018

Accesso al documento

10.1007/s40120-018-0115-y

Altri file e collegamenti

Link to publication in Scopus

Cita questo

@article{bed70c7305474228b5dec5b420b1350c,

title = "Letter to the Editor Regarding: A Comprehensive Review on Copemyl {\textregistered}",

keywords = "Equivalence, Follow-on glatiramer acetate, Glatiramer acetate, Multiple sclerosis",

author = "Giancarlo Comi and Ferdinando Nicoletti and Canonico, {Pier Luigi} and Diego Centonze",

note = "Funding Information: Disclosures. Prof. Giancarlo Comi has received in the past year personal compensation for consulting services and/or speaking activities from Teva, Novartis, Sanofi Genzyme, Merck Serono, Biogen, Roche, Almirall, Cel-gene, Forward Pharma, Medday. Prof. Ferdi-nando Nicoletti has received in the last 3 years consultancy fees from Biogen, Lundbeck, Novartis, Alfa-Sigma, FB-Health, Roche, Otsuka, Janssen, and Teva. Prof. Pier Luigi Canonico has received in the last 3 years honoraria, consultancy fees or paid testimony from AbbVie, Amgen, Amicus Therapeutics, Angelini, Astra Zeneca, Biogen, Biomarin, Boheringer Ingel-heim, Celgene, CSL-Behring, Daiichi Sankyo, Eli Lilly, Incyte Biosciences, Intercept, Jazz Pharmaceuticals, Laboratoire CTRS, Leo Pharma, Lundbeck, Menarini, Merck, MSD, Novo Nordisk, Otsuka, Roche, Sage Therapeutics, Sanofi, Shire, Takeda, Tesaro, Teva, UCB. Prof. Diego Centonze is an Advisory Board member of Almirall, Bayer Schering, Biogen, GW Pharmaceuticals, Merck Serono, Novartis, Roche, Sanofi-Genzyme, Teva and received honoraria for speaking or consultation fees from Almirall, Bayer Schering, Biogen, GW Pharmaceuticals, Merck Serono, Novartis, Roche, Sanofi-Gen-zyme, Teva. He is also the principal investigator in clinical trials for Bayer Schering, Biogen, Merck Serono, Mitsubishi, Novartis, Roche, Sanofi-Genzyme, Teva. His preclinical and clinical research was supported by grants from Bayer Schering, Biogen Idec, Celgene, Merck Serono, Novartis, Roche, Sanofi-Genzyme and Teva.",

year = "2018",

month = dec,

day = "1",

doi = "10.1007/s40120-018-0115-y",

language = "English",

volume = "7",

pages = "385--390",

journal = "Neurology and Therapy",

issn = "2193-8253",

publisher = "Springer Healthcare",

number = "2",

}

TY - JOUR

T1 - Letter to the Editor Regarding

T2 - A Comprehensive Review on Copemyl ®

AU - Comi, Giancarlo

AU - Nicoletti, Ferdinando

AU - Canonico, Pier Luigi

AU - Centonze, Diego

N1 - Funding Information: Disclosures. Prof. Giancarlo Comi has received in the past year personal compensation for consulting services and/or speaking activities from Teva, Novartis, Sanofi Genzyme, Merck Serono, Biogen, Roche, Almirall, Cel-gene, Forward Pharma, Medday. Prof. Ferdi-nando Nicoletti has received in the last 3 years consultancy fees from Biogen, Lundbeck, Novartis, Alfa-Sigma, FB-Health, Roche, Otsuka, Janssen, and Teva. Prof. Pier Luigi Canonico has received in the last 3 years honoraria, consultancy fees or paid testimony from AbbVie, Amgen, Amicus Therapeutics, Angelini, Astra Zeneca, Biogen, Biomarin, Boheringer Ingel-heim, Celgene, CSL-Behring, Daiichi Sankyo, Eli Lilly, Incyte Biosciences, Intercept, Jazz Pharmaceuticals, Laboratoire CTRS, Leo Pharma, Lundbeck, Menarini, Merck, MSD, Novo Nordisk, Otsuka, Roche, Sage Therapeutics, Sanofi, Shire, Takeda, Tesaro, Teva, UCB. Prof. Diego Centonze is an Advisory Board member of Almirall, Bayer Schering, Biogen, GW Pharmaceuticals, Merck Serono, Novartis, Roche, Sanofi-Genzyme, Teva and received honoraria for speaking or consultation fees from Almirall, Bayer Schering, Biogen, GW Pharmaceuticals, Merck Serono, Novartis, Roche, Sanofi-Gen-zyme, Teva. He is also the principal investigator in clinical trials for Bayer Schering, Biogen, Merck Serono, Mitsubishi, Novartis, Roche, Sanofi-Genzyme, Teva. His preclinical and clinical research was supported by grants from Bayer Schering, Biogen Idec, Celgene, Merck Serono, Novartis, Roche, Sanofi-Genzyme and Teva.

PY - 2018/12/1

Y1 - 2018/12/1

KW - Equivalence

KW - Follow-on glatiramer acetate

KW - Glatiramer acetate

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=85058970157&partnerID=8YFLogxK

U2 - 10.1007/s40120-018-0115-y

DO - 10.1007/s40120-018-0115-y

M3 - Letter

SN - 2193-8253

VL - 7

SP - 385

EP - 390

JO - Neurology and Therapy

JF - Neurology and Therapy

IS - 2

ER -